India, June 17 -- Biogen Inc. (BIIB) has agreed to acquire RayThera Inc., a privately held biotechnology company developing small-molecule therapies in immunology, in a transaction valued up to $1 billion. The deal includes an upfront payment along with additional clinical and regulatory milestone payments tied to further development progress.
RayThera's pipeline includes multiple anti-inflammatory assets designed to target immune-mediated diseases across a range of indications. Its lead candidate is expected to enter Phase 1 development in early Q3 2026, making the first clinical program to advance under Biogen's ownership once the acquisition closes.
Biogen said the acquisition strengthens its long-term strategy to expand deeper into im...